Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JUPITER NEUROSCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JUPITER NEUROSCIENCES's position in the market.
Jupiter Neurosciences (NASDAQ: JUNS) issued a statement addressing recent market volatility and highlighting its business strategy. The company is developing JOTROL™, a resveratrol-based platform, with multiple Phase 2 trials scheduled within 12 months following successful Phase 1 safety data. The company targets CNS disorders including Alzheimer's, Parkinson's, and rare diseases, addressing market opportunities exceeding $50 billion.
Jupiter recently partnered with Zina Biopharmaceuticals and Catalent Pharma Solutions for its planned Phase 2a Parkinson's disease study. The company secured $1.76 million in NIH funding, has $16 million in grants under review, and raised $11 million in its December 2024 IPO. Jupiter plans to launch a direct-to-consumer product line in 2025, focusing on longevity and aging markets, to generate near-term revenue while advancing its pharmaceutical pipeline.
Jupiter Neurosciences (NASDAQ: JUNS) has announced a manufacturing agreement with Catalent Pharma Solutions for the production of JOTROL™ softgel capsules to support its upcoming Phase 2a clinical trial in Parkinson's disease. The agreement covers the manufacture of both active and placebo batches under CGMP standards.
JOTROL, Jupiter's proprietary resveratrol-based therapeutic, is designed to enhance bioavailability while reducing gastrointestinal side effects. The Phase 2a trial will evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of JOTROL in Parkinson's patients over three months.
The company notes that Parkinson's disease affects over 10 million people globally, with its therapeutics market projected to exceed $14 billion by 2030. Jupiter is also pursuing strategic partnerships to develop JOTROL for other indications, including Alzheimer's and other neurodegenerative diseases.
Jupiter Neurosciences (NASDAQ: JUNS) has announced a strategic partnership with Zina Biopharmaceuticals to advance its Phase 2a clinical trial for Parkinson's disease. The trial will evaluate JOTROL™, Jupiter's patented resveratrol-based therapeutic platform, focusing on safety, tolerability, and pharmacokinetics/pharmacodynamics in Parkinson's patients.
JOTROL's micellar formulation addresses historical resveratrol limitations by enhancing bioavailability while reducing gastrointestinal side effects. Preclinical studies have shown promise in reducing neurodegeneration biomarkers. Under the agreement, Zina will provide comprehensive services including protocol design, regulatory strategy, and trial site selection.
The partnership aims to accelerate development for the Parkinson's market, which affects over 10 million people globally and is projected to exceed $14 billion by 2030. Jupiter is also exploring additional partnerships to expand JOTROL's applications in other neuroinflammatory and metabolic disorders.
Jupiter Neurosciences (NASDAQ: JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in upcoming clinical trials of their JOTROL™ platform. This shift aims to enhance treatments for neurodegenerative diseases, longevity, and aging. The NLRP3 inflammasome is linked to CNS disorders, metabolic diseases, and aging-related conditions. JOTROL overcomes resveratrol’s issues of poor bioavailability and gastrointestinal side effects, reaching therapeutic plasma levels and crossing the blood-brain barrier.
CEO Christer Rosén emphasized JOTROL’s potential for diseases like Parkinson’s and Alzheimer’s, with preclinical studies showing positive results for Parkinson’s at the University of Miami. The company is refining its Alzheimer’s strategy, leveraging a prior Phase I study. The recent U.S. Senate's
Jupiter Neurosciences (Nasdaq: JUNS) has completed its initial public offering, raising $11 million through the sale of 2,750,000 shares at $4.00 per share. Trading began on the Nasdaq Capital Market on December 3, 2024, under the symbol 'JUNS'.
The proceeds will fund the Phase II clinical trial of JOTROL™ for Parkinson's Disease, strategic agreements in South-East Asia, R&D for new products, license fees to Aquanova AG, debt repayment, and working capital. Dominari Securities led the underwriting, with Revere Securities as co-manager.
Jupiter Neurosciences (JUNS) has announced the pricing of its initial public offering of 2,750,000 shares at $4.00 per share, expecting to raise $11 million in gross proceeds. Trading will commence on Nasdaq Capital Market on December 3, 2024, under the symbol 'JUNS'. The company plans to use proceeds to fund Phase II clinical trials of JOTROL™ for Parkinson's Disease, expand business in South-East Asia, conduct R&D, pay license fees to Aquanova AG, repay debt, and support working capital. The offering is led by Dominari Securities with Revere Securities as co-manager.
FAQ
What is the current stock price of JUPITER NEUROSCIENCES (JUNS)?
What is the market cap of JUPITER NEUROSCIENCES (JUNS)?
